• Alternative treatment strategies with drugs not dependent on cytochrome P450 2C19
should be considered for multidrug therapy in patients at high risk for recurrent myocardial …

Background: Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active
metabolite. The clinical significance of this drug interaction is unknown. Methods: We …

With this background, the recently postulated drug interaction between proton pump
inhibitors (PPIs) and clopidogrel is in a league of its own, spawning a flurry of research and …

Objective: To evaluate the interaction between clopidogrel and proton pump inhibitors
(PPIs). Data Sources: Literature retrieval was accessed through PubMed (1980–January …

Background Proton pump inhibitors (PPIs) are usually prescribed to patients undergoing
dual antiplatelet therapy to decrease the risk of gastrointestinal bleeding. Recent studies …

Objective To measure the association between use of proton pump inhibitors and a range of
harmful outcomes in patients using clopidogrel and aspirin. Design Observational cohort …

Current consensus recommendations state that patients prescribed clopidogrel plus aspirin
should receive a proton pump inhibitor (PPI) to reduce gastrointestinal bleeding. Clopidogrel …

Background Data from pharmacokinetic and pharmacodynamic studies indicate that the
adverse clopidogrel–proton pump inhibitor (PPI) interaction may vary between PPIs, with …

Clopidogrel is a widely used antiplatelet agent for the secondary prevention of
cardiovascular events in patients with stable coronary heart disease, acute coronary …

Background Several studies have suggested that proton-pump inhibitors (PPIs), mostly
omeprazole, interact with clopidogrel efficacy by inhibiting the formation of its active …